Today’s Top Three in Pharma 011609

Will Pfizer cut its sales force again, by nearly one third? Bloomberg reports that Pfizer may eliminate nearly one-third of its sales force. The plan, which is apparently under consideration by senior management, would be to eliminate as many as 2,400 reps and managers, according to Bloomberg. Plus, the Motley fool weighs the pros and cons (mostly cons) about looking at a major acquisition in the near term.

Novartis gets a big contract to build a new flu vaccine plant. The U.S. Department of Health and Human Services granted the eight-year contract to build and run a vaccine manufacturing site in Holly Springs, North Carolina, Novartis said.

J&J wins a round in the never-ending legal wars with Boston Scientific over stent patents. “The (lower) court erred as a matter of law in failing to hold the ‘536 (stent) patent to have been obvious,” the appeals court said. “Obviousness” is grounds for stripping Boston Scientific of the patent. “We reverse the judgment,” the appeals court said.

PLUS – Talking Pharma Talking – a summary of this week’s Real-time Communications conference, which featured great sessions by Pfizer and J&J folks.

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs.